Acasti Pharma, Inc. - (ACST): Price and Financial Metrics


Acasti Pharma, Inc. - (ACST): $0.43

-0.01 (-1.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ACST Stock Price Chart Interactive Chart >

Price chart for ACST

ACST Price/Volume Stats

Current price $0.43 52-week high $1.35
Prev. close $0.44 52-week low $0.34
Day low $0.42 Volume 23,300
Day high $0.44 Avg. volume 127,223
50-day MA $0.61 Dividend yield N/A
200-day MA $0.67 Market Cap 19.18M

Acasti Pharma, Inc. - (ACST) Company Bio


Acasti Pharma Inc operates as pharmaceutical company. The Company develops drugs for cardiovascular diseases. Acasti offers omega-3 phospholipids a major component of cell membranes.


ACST Latest News Stream


Event/Time News Detail
Loading, please wait...

ACST Latest Social Stream


Loading social stream, please wait...

View Full ACST Social Stream

Latest ACST News From Around the Web

Below are the latest news stories about ACASTI PHARMA INC that investors may wish to consider to help them evaluate ACST as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

The biggest pre-market stock movers are making waves on Wednesday with huge gainers and losers worth watching this morning!

William White on InvestorPlace | March 22, 2023

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST) a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it has applied and received approval for a voluntary delisting of its common shares from the TSX Venture Exchange ("TSXV"). The delisting from the TSXV will not affect the Company's listing on the NASDAQ Capital Market (the "NASDAQ"). The common shares will continue to trade on

Yahoo | March 13, 2023

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference

Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced Jan D'alvise, CEO, will present and host one-on-one meetings with investors at the Oppenheimer 33rd Annual Healthcare Conference, held virtually and taking place on March 13-15, 2023.

Yahoo | March 8, 2023

We're Hopeful That Acasti Pharma (CVE:ACST) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | March 4, 2023

Acasti Pharma Recognizes Rare Disease Day

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, recognizes and celebrates Rare Disease Day (February 28), as established by the European Organization for Rare Diseases.

Yahoo | February 28, 2023

Read More 'ACST' Stories Here

ACST Price Returns

1-mo -27.54%
3-mo -17.95%
6-mo -29.42%
1-year -65.04%
3-year -85.10%
5-year -94.68%
YTD -14.17%
2022 -60.24%
2021 -51.54%
2020 -86.73%
2019 195.18%
2018 -11.70%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6871 seconds.